

1 **1.Title:** Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

2

3 **2.Authors:** Jian Liu\*<sup>1</sup>, YuYing Jiang\*<sup>2</sup>, ZiYue Diao\*<sup>1</sup>, DanDan Chen<sup>1</sup>, RuiYuan Xia<sup>1</sup>,  
4 BingWei Wang#<sup>3</sup>, Shuo Yang#<sup>2</sup>, ZhiQiang Yin#<sup>1</sup>.

5 \* Jian Liu, YuYing Jiang and ZiYue Diao contributed equally to this work.

6 <sup>1</sup>Department of Dermatology, First Affiliated Hospital of Nanjing Medical University,  
7 Nanjing, China.

8 <sup>2</sup>Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring  
9 Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative  
10 Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi  
11 People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical  
12 Center, Nanjing Medical University, Nanjing, China.

13 <sup>3</sup>Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin  
14 Avenue, Nanjing, China.

15

16 **3.Corresponding authors:**

17 *ZhiQiang Yin*, Email: yinzhiqiang@njmu.edu.cn

18 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, 300  
19 Guangzhou Road, Nanjing, Jiangsu 210029, China

20 *Shuo Yang*, Email: shuoyang01@njmu.edu.cn

21 Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring  
22 Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative  
23 Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi  
24 People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical  
25 Center, Nanjing Medical University, Nanjing, China, 211166

26 *BingWei Wang*, Email: bingweiwang@njucm.edu.cn

27 Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin Avenue,  
28 Nanjing, China, 210023

29

30 **4.Funding sources:** This work was supported by the National Natural Science Foundation of  
31 China (82073439 and 82373475).

32

33 **5.Conflicts of Interest:** None declared.

34

35 **6.Manuscript word count:** 2466; **Abstract word count:** 169; **References:** 46; **Figures:** 4;

36

37 **7.Keywords:** psoriasis; neutrophil; pyroptosis; gasdermin D; treatment

38

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

39 **Declarations**

40 Ethics approval and consent to participate:

41 All mice were kept in a barrier facility, and all animal experiments were conducted in  
42 accordance with the procedure approved by the Ethical Review Committee for  
43 Laboratory Animal Welfare of the Nanjing Medical University (IACUC-2203023).  
44 Human skin tissue samples were obtained from the Department of Dermatology,  
45 Jiangsu Provincial People's Hospital, which was approved by the Ethics Committee of  
46 the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province  
47 Hospital), Ethics Number: 2020-SRFA-101, and informed consent was obtained from  
48 all study participants.

49

50 Consent for publication:

51 All authors agreed with the submission of this manuscript to *eLife* and consent for  
52 publication was obtained.

53

54 Availability of data and material:

55 The data and materials are available from the corresponding authors upon reasonable  
56 request.

57

58 Competing interests: None declared.

59

60 Funding: This work was supported by the National Natural Science Foundation of  
61 China (82073439 and 82373475).

62

63 Authors' contributions:

64 Jian Liu: Data curation, Investigation, Methodology and Writing - original draft

65 YuYing Jiang and ZiYue Diao: Data curation, Investigation and Methodology

66 DanDan Chen and RuiYuan Xia: Methodology

67 BingWei Wang, Shuo Yan and ZhiQiang Yin: Conceptualization, Project  
68 administration, Supervision and Writing - review & editing

69

70 Acknowledgements: None.

71

72

73

74

75

76

77

78

79

80

81

82

83 **Abstract**

84 Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis  
85 involves abnormal accumulation of neutrophils and T-cell related abnormalities.  
86 Pyroptosis is a type of regulated cell death associated with innate immunity, but its  
87 role in psoriasis is unclear. In this study, we found that *gasdermin D (Gsdmd)* is higher  
88 in human psoriatic skin than that in normal skin, and in imiquimod-induced  
89 psoriasis-like mouse skin, the expression of *Gsdmd* was most significantly altered in  
90 neutrophils and *Il1b* was also mainly expressed in neutrophils. Immunohistochemical  
91 staining of serial sections of skin lesions from psoriasis patients and healthy control  
92 also showed that GSDMD expression is higher in psoriasis lesion, especially in  
93 neutrophils. *Gsdmd* deficiency mitigates psoriasis-like inflammation in mice.  
94 GSDMD in neutrophils contributes to psoriasis-like inflammation, while *Gsdmd*  
95 depletion in neutrophils attenuates the development of skin inflammation in psoriasis  
96 and reduces the release of the inflammatory cytokines. We found that neutrophil  
97 pyroptosis is involved in and contributes to psoriasis inflammation, which provides  
98 new insights into the treatment of psoriasis by targeting neutrophil pyroptosis.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114 Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

115

## 116 **1. Introduction**

117 Psoriasis is an autoimmune disease that involves multiple systems and manifests  
118 primarily as plaques and scaling. The incidence of psoriasis displays significant  
119 variation across populations, with estimates ranging from 0.47% in China to 8.5% in  
120 Norway, and 3.0% among adults in the United States[1-3]. The etiology of psoriasis is  
121 multi-factorial and involves a complex interplay of genetic, environmental, infectious  
122 and lifestyle factors. Previous studies have suggested that the pathogenesis of  
123 psoriasis is related to the involvement of various cells, including immune cells,  
124 keratinocytes and stromal cells, and the underlying mechanism is complex[4]. The  
125 participation of immune cells remains a research focus. Most biologics utilized to  
126 treat psoriasis presently target the immune pathway. Current studies suggest that the  
127 interleukin 23 (IL-23)/T-helper 17 (Th17) immune axis is the primary immune  
128 pathway involved in psoriasis pathogenesis[5]. Th17 cells play a significant role in  
129 the pathogenesis of many autoimmune and inflammatory diseases. Th17-derived  
130 proinflammatory cytokines, such as IL-17A, IL-17F, and IL-22 are critical in the  
131 development of psoriasis[6]. Studies have shown that IL-17A contributes to both an  
132 adaptive immune circuit involving specific T-cell subsets and an innate axis between  
133 keratinocytes and neutrophils[7]. Except for Th17 cells, Neutrophils within the skin  
134 are a hallmark feature of psoriasis. Neutrophils accumulate in the dermis and  
135 epidermis, resulting in the formation of Kogoj pustules and Munro microabscesses [8].  
136 Neutrophils are increased in the skin and blood of patients with psoriasis,[9] and  
137 promote psoriasis by secreting proinflammatory mediators and proteases through  
138 degranulation or forming neutrophil extracellular traps[10-12]. Nevertheless, the  
139 mechanisms by which neutrophils promote and exacerbate inflammation in psoriasis  
140 remain under investigation.

141 Pyroptosis is a type of regulated cell death triggered by the inflammasome and  
142 mediated by the gasdermin family[13]. Gasdermin D (GSDMD) is currently the most  
143 extensively researched member of the gasdermin family. After perturbations of  
144 extracellular or intracellular homeostasis related to innate immunity, the classical and  
145 non-classical pathways activate caspase 1 and caspase 4/5/11 (caspase 4/5 in humans  
146 and caspase 11 in mice)[14], and the activated caspases cleave GSDMD into its  
147 N-terminal and C-terminal fragments[15]. The N-terminus of GSDMD forms a  
148 transmembrane pore, which releases inflammatory mediators [16, 17]and results in  
149 proinflammatory cell death[18]. In recent years, there has been a focus on the role of  
150 pyroptosis in infections, tumors, and autoimmune diseases[19-22] due to its potential  
151 to cause inflammatory diseases when occurring excessively.

152 While previous studies have showed that the expression of GSDMD is increased  
153 in lesions of patients with psoriasis[23], and the pyroptosis of keratinocytes plays a  
154 role in inflammation seen in psoriasis[24]. However, the exact contribution of  
155 immune cell pyroptosis to the development of psoriasis remains unclear. Therefore,  
156 our study aimed to investigate the role of GSDMD-mediated immune cell pyroptosis  
157 in psoriasis.

158

## 159 **2. Methods**

### 160 2.1 Experimental animals

161 All mice were of the species *Mus musculus* (C57BL/6). All experiments were  
162 performed with female mice (6–8 weeks old). The *Gsdmd*<sup>-/-</sup> mice were provided by Dr.  
163 Feng Shao (National Institute of Biological Sciences, Beijing, China). The *Gsdmd*<sup>fl/fl</sup>  
164 mice were generated using conditional gene targeting methods as described  
165 previously[25]. All mice were kept in a barrier facility, and all animal experiments  
166 were conducted in accordance with the procedure approved by the Ethical Review  
167 Committee for Laboratory Animal Welfare of the Nanjing Medical University  
168 (IACUC-2203023).

### 169 2.2 Psoriasis-like mouse model

170 Psoriasis-like mice were induced by 5% imiquimod (IMQ) cream as previously  
171 described [26]. Mice received a topical application of 32.5 mg 5% IMQ on the shaved  
172 dorsal skin for 4 days, and control mice were given the same dose of Vaseline for 4  
173 days. The skin was examined every day, and the dorsa were photographed. The mice  
174 were sacrificed by cervical dislocation on day 5, and their skin and serum were  
175 collected for the next experiment.

### 176 2.3 Western blot

177 Mice back skin tissues were lysed in lysis buffer solution [150 mM NaCl, 10 mM tris  
178 (pH 7.4), 5 mM EDTA, 1 mM EGTA, and 0.1%NP-40] supplemented with 1 mM  
179 phenylmethylsulphonyl fluoride, and complete protease inhibitor “cocktail”  
180 [Sigma-Aldrich]), followed by tissue homogenization and incubation for 60 min at  
181 4°C. The lysates were centrifuged for 10 min at 14,000 g, and supernatants were  
182 denatured with SDS buffer, and boiled for 10 min. Proteins were separated by SDS–  
183 polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes.  
184 The membranes were immunoblotted with primary antibodies and proteins detected  
185 with appropriate secondary anti-rabbit antibody conjugated to fluorescence.  
186 Immunoreactivity was visualized by the Odyssey Imaging System (LI-COR  
187 Biosciences).

### 188 2.4 Enzyme-linked immunosorbent assay

189 Homogenized the mouse back skin tissues (the method is the same as before), and  
190 collected the supernatant. Supernatant were collected and measured for the level of  
191 IL-1 $\beta$  (DY401) and IL-6 (DY406) according to manufacturer’s instructions by  
192 sandwich enzyme-linked immunosorbent assay (ELISA) (R&D System).

### 193 2.5 Immunofluorescence and Immunohistochemistry staining

194 For immunofluorescence, the mice skin tissues were collected, fixed in 4% buffered  
195 formaldehyde, and embedded in paraffin. Tissue sections were incubated at 4°C  
196 overnight with primary antibody to GSDMD (Abcam, 1:300) and Ly6G (BDscience,  
197 1:100). Slides were then incubated with indicated secondary antibodies. TUNEL  
198 staining was carried out with staining kit (Servicebio). The nuclei were counterstained  
199 with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Slides were dried and  
200 mounted using ProLong Antifade mounting medium (Beyotime Biotechnology).  
201 Slides were visualized using a Nikon 50i fluorescence microscope. For

202 immunohistochemical staining, human skin tissue samples were obtained from the  
203 Department of Dermatology, Jiangsu Provincial People's Hospital. Our study was  
204 approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical  
205 University (Jiangsu Province Hospital), Ethics Number: 2020-SRFA-101, and  
206 informed consent was obtained from all study participants. Sections were blocked and  
207 incubated with primary antibodies to GSDMD (Abcam, 1:1000) and CD66b  
208 (Biologend, 1:80) after heat-induced antigen retrieval. Slides were then incubated with  
209 horseradish peroxidase-conjugated secondary antibodies. Diaminobenzidine was used  
210 for detection. Images were captured with a Nikon 50i microscope. Images were  
211 processed using ImageJ 1.53c and AdobePhotoshopCS6 software.

## 212 2.6 Flow cytometry (FCM) and Fluorescence Activated Cell Sorting (FACS)

213 For FCM, skin tissue was digested into single cell suspensions with collagenase P  
214 (ROCHE, 1mg/mL), DNaseI (ROCHE, 100 $\mu$ g/ml), and HAase (ABSIN, 10 $\mu$ g/ mL) at  
215 37°C for 1 hour. Single cell suspensions were stained with anti-CD45-Alexa Flour  
216 700 (eBioscience, 1:400), anti-Ly6G-eFlour 450 (eBioscience, 1:400), and FVD  
217 eFlour 506 (eBioscience,1:1000) for Flow cytometry (Thermo). After the mice were  
218 euthanized, the long bones were separated and the bone marrow was aspirated with a  
219 sterile syringe. Single cell suspension was stained with anti-CD45-Alexa Flour 700  
220 (eBioscience, 1:400), anti-CD11b-Percp-cy5.5 (eBioscience, 1:400) and  
221 anti-Ly6G-eFlour 450(eBioscience, 1:400) for FACS analysis (Thermo),  
222 CD45<sup>+</sup>FVD<sup>-</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils were obtained by FACS. All flow cytometry  
223 analyses were performed on an Attune NxT Flow Cytometer (Thermo Fisher  
224 Scientific), and data were analyzed using FlowJo 10 software.

## 225 2.7 Neutrophil depletion

226 An injection of anti-Ly6G antibody (Selleck, 200 $\mu$ g) was given on day-1 and day2  
227 during continuous IMQ application to deplete neutrophil in mice.

## 228 2.8 Statistical analysis

229 Data were analyzed using Prism 8 (GraphPad, San Diego, CA, USA). Comparisons  
230 between two groups were analyzed by using unpaired Student's t-test. All data are  
231 presented as the mean  $\pm$  SEM and are representative of at least three independent  
232 experiments. P < 0.05 was considered indicative of statistical significance. \* p  $\leq$  0.05,  
233 \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p  $\leq$  0.0001, ns p > 0.05.

234

## 235 3. Results

### 236 3.1 The GSDMD-mediated pyroptosis is activated in psoriasis.

237 By searching the GEO database, we found that *Gsdmd* is higher in human  
238 psoriatic skin than that in normal skin, and the similar trend was seen in IMQ-induced  
239 psoriasis model mice compared to controls (**Fig.1a**). Immunohistochemical staining  
240 of serial sections of skin lesions from psoriasis patients and healthy control also  
241 showed that GSDMD expression is higher in psoriasis patients (**Fig.1b**). To further  
242 elucidate the presence of pyroptosis in psoriasis, we induced a psoriasis-like mouse  
243 model by applying IMQ (**Fig.1c**). The lesions of the mice were collected for western  
244 blotting, our results indicated that the IMQ-treated group not only has elevated  
245 expression of caspase 1 and GSDMD relative to controls, but also shows functional

246 cleavage of 30KD GSDMD N fragment (**Fig.1d-e**). Hence, the activation of  
247 pyroptosis-associated molecules was found in psoriasis lesions.

248

249 3.2 GSDMD deficiency mitigates psoriasis-like inflammation in mice.

250 Given the particular elevation of GSDMD levels in psoriasis, we questioned  
251 whether GSDMD contributed to psoriasis pathogenesis. We treated WT and GSDMD  
252 deficient mice with IMQ to induce psoriasis (**Fig.1c**). We found that the psoriasis area  
253 and severity index (PASI)scores were significantly lower in *Gsdmd*<sup>-/-</sup> mice than WT  
254 after 4 days of IMQ application (**Fig.2a-b**). Moreover, indicators to assess the severity  
255 of psoriasis, including acanthosis, parakeratosis, and microabscess formation as well  
256 as infiltration of leukocytes, were less pronounced in *Gsdmd*<sup>-/-</sup> mice compared with  
257 WT (**Fig.2c**). We verified the absence of GSDMD in the skin of *Gsdmd*<sup>-/-</sup> mice by  
258 western blotting and found that after induction of psoriasis in *Gsdmd*<sup>-/-</sup> mice, the  
259 expression and activation of caspase 1, an upstream molecule of pyroptosis, were  
260 decreased (**Fig.2d**). Levels of the pro-inflammatory cytokines in protein and mRNA  
261 were also examined in the skin using ELISA and quantitative PCR, respectively. Our  
262 results showed that the levels of inflammatory cytokines in psoriasis such as IL17a,  
263 TNF- $\alpha$ , IL6, IL-1 $\beta$  and IL18 were substantially higher in the WT mice than in the  
264 *Gsdmd*<sup>-/-</sup> mice (**Fig.2e-f**). These results demonstrated that the absence of GSDMD  
265 ameliorated IMQ-induced psoriasiform dermatitis in mice.

266

267 3.3 Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.

268 Previous studies have shown that pyroptosis occurs in psoriasis[24, 27].  
269 Moreover, neutrophils are critical to the pathogenesis of psoriasis, which is usually  
270 characterized by a high accumulation of neutrophils both in lesions as well as in  
271 blood[28]. Therefore, we wanted to clarify whether neutrophils undergo pyroptosis in  
272 psoriasis. Firstly, we searched the GEO database and found that psoriasis patients'  
273 neutrophils showed higher expression of GSDMD (**Fig.3a**). Serial sections of skin  
274 lesions from psoriasis patients were immunohistochemically stained with CD66b and  
275 GSDMD antibodies. We further found that GSDMD was prominently expressed in  
276 neutrophils, especially in Munro's microabscesses, which were indicated by CD66b in  
277 the patients' skin of both psoriasis vulgaris and pustular psoriasis (**Fig.3b**). Through  
278 database search and analysis, we found that in psoriasis-like mouse skin, the  
279 expression of *Gsdmd* was most significantly altered in neutrophils (**Fig.3c**). Then, we  
280 carried out immunofluorescent analysis of GSDMD in the psoriatic skin tissues of  
281 WT mice and GSDMD-deficient mice used as a negative control. Lymphocyte antigen  
282 6 (Ly6G), a classical neutrophil marker[29, 30], was found to be mainly expressed in  
283 neutrophils in the skin of IMQ-induced psoriasis-like mice (**S1a**). Therefore, we chose  
284 Ly6G as a marker for mouse neutrophils in our experiments. In line with GEO data,  
285 immunofluorescence staining showed that GSDMD was more strongly expressed in  
286 the mice skin of IMQ applied group than control, including the significant localization  
287 of GSDMD in neutrophils (**Fig.3d**). To further confirm that these neutrophils  
288 underwent pyroptosis, we used flow cytometry to stain PI to confirm neutrophil  
289 pyroptosis and performed TUNEL staining on mouse skin after IMQ application to

290 exclude other cell deaths such as apoptosis (**Fig.3e, S1b**), these data suggest that  
291 GSDMD-mediated pyroptosis exists in neutrophils infiltrating into psoriatic lesions as  
292 shown more PI staining but not change in TUNEL staining in neutrophils.

293

294 3.4 GSDMD depletion in neutrophils attenuates the development of skin  
295 inflammation in psoriasis.

296 To investigate the specific effect of neutrophils in psoriasis, we bred *Gsdmd*<sup>fl/fl</sup>;  
297 *S100a8*<sup>cre/+</sup> (cKO) mice to make conditionally knockout GSDMD in neutrophils. There  
298 are many previous studies using S100A8-Cre mice to knockout neutrophil-specific  
299 genes[31, 32]. And we found that *S100a8* is mainly expressed in neutrophils in  
300 psoriasis-like mouse skin (**S1c**). Therefore, we believe that the knockout effect of  
301 GSDMD in cKO mice on other cells is quite small. We isolated bone marrow-derived  
302 neutrophils and demonstrated by immunoblotting that GSDMD expression was  
303 reduced in cKO neutrophil (**Fig.4a**). Then we applied IMQ to the cKO and control  
304 mice (*Gsdmd*<sup>fl/fl</sup>; *S100a8*<sup>+/+</sup>) mice on a continuous basis for 4 days to induce psoriasis.  
305 Our results showed that after induction of psoriasis, cKO mice had milder disease  
306 than controls, as evidenced by reduced PASI scores and the apparent remission of skin  
307 changes shown by HE staining, including acanthosis, parakeratosis, and infiltration of  
308 leukocytes (**Fig.4b-d**). And the lower levels of inflammatory cytokines, including  
309 IL-17a, TNF- $\alpha$ , IL-6, IL-1 $\beta$  and IL-18, were also showed in cKO mice (**Fig.4e-f**).  
310 Notably, although neutrophil-specific deletion of GSDMD mice showed a reduction  
311 in psoriasis-like symptoms after induction, the reduction was not as pronounced as in  
312 GSDMD full knockout mice, suggesting that additional cellular pyroptosis may also  
313 be involved in psoriasis pathogenesis. To further investigate neutrophilic pyroptosis in  
314 psoriasis, we detected the expression of GSDMD and its N-terminal fragments by WB  
315 in the psoriatic skin of WT mice, *Gsdmd*<sup>-/-</sup> mice and cKO mice. We found that after  
316 psoriasis induction, the GSDMD N-terminus was only weakly expressed in the skin of  
317 cKO mice, whereas it was strongly expressed in WT mice (**Fig4g**), suggesting that  
318 GSDMD-mediated neutrophil pyroptosis is one of the important components of cell  
319 pyroptosis in psoriasis. In addition, we used Ly6G antibody to eliminate neutrophils in  
320 cKO mice and control mice. It was found that the difference in lesions between the  
321 two groups was abolished after neutrophil depletion (**Fig4i, S2a**), indicating that  
322 neutrophil pyroptosis plays an important role in the pathogenesis of  
323 imiquimod-induced psoriasis-like lesions in mice.

324 Considering that pyroptosis is a form of regulated cell death that results in  
325 inflammation, its effects can be linked to the release of inflammatory cytokines  
326 through membrane pores formed by GSDMD. While neutrophils do undergo  
327 pyroptosis, they may exhibit resistance to this cytolytic effect, leading to sustained  
328 cytokine release. IL-1 $\beta$ , a significant inflammatory cytokine of pyroptosis, has a  
329 crucial function in the pathogenesis of psoriasis. The IL-1 $\beta$ -IL-1R pathway promotes  
330 the ailment by regulating IL-17-producing cells in the dermis and stimulating  
331 keratinocytes to magnify inflammatory cascades. Therefore, it is hypothesized that the  
332 occurrence of neutrophil pyroptosis in psoriasis may activate inflammatory pathways  
333 downstream by releasing cytokine IL-1 $\beta$ . In order to further verify our hypothesis, we



334 analyzed publicly available single cell sequencing data. We found that in the skin of  
335 psoriasis-like mice, *Il1b* and *Il6* were mainly expressed in neutrophils, while *Il17a*  
336 was mainly expressed in T cells, *Il18* was mainly expressed in macrophages and  
337 fibroblasts, and *Tnfa* was mainly expressed in macrophages and T cells (**S2b**). This  
338 suggests that neutrophil pyroptosis may affect the secretion of cytokines such as IL-1 $\beta$   
339 and IL-6 by neutrophils, thereby affecting the functions of other immune cells such as  
340 T cells and macrophages, forming a complex inflammatory network in psoriasis and  
341 participating in the pathogenesis of psoriasis.

342

#### 343 4 Discussion

344 In this study, we dissected the role of GSDMD protein, a key pyroptosis  
345 executioner, in the context of psoriasis. We found that GSDMD protein was activated  
346 in the skin of psoriasis, and that GSDMD in neutrophils promotes psoriasis  
347 inflammation through pyroptosis and the release of cytokines. Research on pyroptosis  
348 has tended to focus on infections, tumors, and other acute inflammations. Pyroptosis  
349 is not only involved in the regulation of sepsis, but also mediates sepsis-related organ  
350 damage[33]. This means that while moderate pyroptosis promotes clearance of  
351 pathogens, excessive pyroptosis can lead to uncontrolled inflammatory responses and  
352 promote the onset and development of sepsis[33-35]. Moreover, pyroptosis promotes  
353 severe pancreatitis and associated lung injury through the release of cytokines IL-1 $\beta$   
354 and IL-18[36], and is implicated in acute myocardial injury and spinal cord injury[37,  
355 38]. In addition, GSDMD induced pyroptosis of antigen presenting cells in tumor  
356 microenvironments impairs antigen presentation in response to anti-PD-L1  
357 treatment[22]. Only in recent years, studies have explored the function of pyroptosis  
358 in psoriasis. Iwona Flisiak et al. found that GSDMD expression was significantly  
359 increased in the skin of psoriasis patients, suggesting that it may be involved in the  
360 pathogenesis of psoriasis[23]. Xu Chen et al. reported that GSDMD-mediated  
361 keratinocyte pyroptosis promotes excessive proliferation and abnormal differentiation  
362 induced by the immune microenvironment in psoriatic skin inflammation, thus  
363 contributing to the pathogenesis of psoriasis[24]. In addition, there are some studies  
364 on pyroptosis-related proteins upstream of GSDMD, such as NLPR3 inflammasome  
365 and AIM2 inflammasome, which are involved in and promote psoriasis through  
366 downstream inflammatory cytokines[27, 39, 40].

367 Consistent with earlier research, our study found that the expression of GSDMD  
368 and its upstream molecule caspase 1 was upregulated in the skin of psoriasis patients  
369 and psoriasis-like mice, indicating that the pyroptosis pathway is activated in psoriasis  
370 skin lesions. Knockout of GSDMD in vivo is effective in significantly ameliorating  
371 IMQ-induced psoriasis-like lesions and reducing the level of skin inflammation,  
372 which also notably reduces the expression of the pyroptosis-inducing inflammatory  
373 cytokine IL-1 $\beta$ . In our study, we found that the upregulated GSDMD signal was more  
374 significant in neutrophils in both human and animal tissues. In addition, specific  
375 knockout of GSDMD in neutrophils in vivo can also yield results consistent with  
376 GSDMD KO mice, although not as obvious as in KO mice. Our study is for the first  
377 time demonstrating that GSDMD-mediated neutrophil pyroptosis in psoriasis is

378 involved in psoriatic inflammation and may affect the inflammatory network in  
379 psoriasis. Considering the role and early recruitment of neutrophils in psoriasis[28,  
380 41], it is readily accepted that neutrophils act as innate immune cells in response to  
381 changes in the microenvironment to initiate pyroptosis signaling and release cytokines  
382 to engage and maintain psoriasis inflammation. IL-1 $\beta$  released by pyroptosis may  
383 amplify the inflammatory cascade through the IL-1 $\beta$ -IL-1R pathway via direct  
384 regulation of dermal IL-17-producing cells and stimulation of keratinocytes[42],  
385 thereby contributing to skin inflammation and psoriasis. In addition, the unique  
386 resistance of neutrophils to pyroptosis[43] makes it reasonable for them to  
387 continuously release cytokines after activation of the pyroptosis pathway and further  
388 stimulate skin inflammation.

389 Nevertheless, combining previous studies and our findings, we can believe that  
390 GSDMD-mediated pyroptosis, which is a dynamic biological process, particularly  
391 neutrophil pyroptosis, is involved in the inflammation of psoriasis, especially in the  
392 early stage. This provides a potential basis for the possible use of drugs targeting  
393 pyroptosis, especially drugs targeting neutrophil pyroptosis, in the treatment of  
394 psoriasis. Dimethyl fumarate is a type of medicine widely used to treat psoriasis in  
395 Europe[44, 45]. The latest research proves that dimethyl fumarate can inhibit the  
396 function of GSDMD and thereby inhibit pyroptosis-related inflammation[46].

397 There is some limitation in our study such as the lack of exploration of upstream  
398 signaling involved in neutrophil pyroptosis along with its specific molecular  
399 mechanisms. Nevertheless, our study showed that neutrophil pyroptosis is involved in  
400 and contributes to psoriasis inflammation, indicating potential avenues and  
401 foundations for novel psoriasis treatment strategies.

402

#### 403 **References:**

- 404 1. Pezzolo, E. and L. Naldi, *Epidemiology of major chronic inflammatory immune-related*  
405 *skin diseases in 2019*. Expert review of clinical immunology, 2020. **16**(2): p. 155-166.
- 406 2. Armstrong, A.W., et al., *Psoriasis prevalence in adults in the United States*. JAMA  
407 dermatology, 2021. **157**(8): p. 940-946.
- 408 3. Ding, X., et al., *Prevalence of psoriasis in China: a population-based study in six cities*.  
409 European Journal of Dermatology, 2012. **22**(5): p. 663-667.
- 410 4. Guo, J., et al., *Signaling pathways and targeted therapies for psoriasis*. Signal  
411 Transduction and Targeted Therapy, 2023. **8**(1): p. 437.
- 412 5. Girolomoni, G., et al., *The role of IL-23 and the IL-23/TH 17 immune axis in the*

- 413 *pathogenesis and treatment of psoriasis*. Journal of the European Academy of  
414 Dermatology and Venereology, 2017. **31**(10): p. 1616-1626.
- 415 6. Li, B., et al., *The role of Th17 cells in psoriasis*. Immunologic research, 2020. **68**: p.  
416 296-309.
- 417 7. Reich, K., et al., *Evidence that a neutrophil-keratinocyte crosstalk is an early target of*  
418 *IL-17A inhibition in psoriasis*. Experimental dermatology, 2015. **24**(7): p. 529-535.
- 419 8. Schön, M.P., S.M. Broekaert, and L. Erpenbeck, *Sexy again: the renaissance of*  
420 *neutrophils in psoriasis*. Experimental dermatology, 2017. **26**(4): p. 305-311.
- 421 9. Rodriguez-Rosales, Y.A., et al., *Immunomodulatory aged neutrophils are augmented*  
422 *in blood and skin of psoriasis patients*. Journal of Allergy and Clinical Immunology,  
423 2021. **148**(4): p. 1030-1040.
- 424 10. Wang, Z. and D. Shi, *Research progress on the neutrophil components and their*  
425 *interactions with immune cells in the development of psoriasis*. Skin Research and  
426 Technology, 2023. **29**(7): p. e13404.
- 427 11. Chen, J., et al., *Neutrophils enhance cutaneous vascular dilation and permeability to*  
428 *aggravate psoriasis by releasing matrix metalloproteinase 9*. Journal of Investigative  
429 Dermatology, 2021. **141**(4): p. 787-799.
- 430 12. Shao, S., et al., *Neutrophil extracellular traps promote inflammatory responses in*  
431 *psoriasis via activating epidermal TLR4/IL-36R crosstalk*. Frontiers in immunology,  
432 2019. **10**: p. 746.
- 433 13. Galluzzi, L., et al., *Molecular mechanisms of cell death: recommendations of the*  
434 *Nomenclature Committee on Cell Death 2018*. Cell Death & Differentiation, 2018.

- 435           25(3): p. 486-541.
- 436   14.   Kesavardhana, S., R.S. Malireddi, and T.-D. Kanneganti, *Caspases in cell death,*  
437           *inflammation, and pyroptosis.* Annual review of immunology, 2020. **38**: p. 567-595.
- 438   15.   Kovacs, S.B. and E.A. Miao, *Gasdermins: effectors of pyroptosis.* Trends in cell  
439           biology, 2017. **27**(9): p. 673-684.
- 440   16.   Evavold, C.L., et al., *The pore-forming protein gasdermin D regulates interleukin-1*  
441           *secretion from living macrophages.* Immunity, 2018. **48**(1): p. 35-44. e6.
- 442   17.   Heilig, R., et al., *The Gasdermin-D pore acts as a conduit for IL-1 $\beta$  secretion in mice.*  
443           European journal of immunology, 2018. **48**(4): p. 584-592.
- 444   18.   Banerjee, I., et al., *Gasdermin D restrains type I interferon response to cytosolic DNA*  
445           *by disrupting ionic homeostasis.* Immunity, 2018. **49**(3): p. 413-426. e5.
- 446   19.   You, R., et al., *Pyroptosis and its role in autoimmune disease: a potential therapeutic*  
447           *target.* Frontiers in immunology, 2022. **13**: p. 841732.
- 448   20.   Fang, Y., et al., *Pyroptosis: a new frontier in cancer.* Biomedicine & Pharmacotherapy,  
449           2020. **121**: p. 109595.
- 450   21.   Yu, P., et al., *Pyroptosis: mechanisms and diseases.* Signal transduction and targeted  
451           therapy, 2021. **6**(1): p. 128.
- 452   22.   Jiang, Y., et al., *Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint*  
453           *blockade.* Cell Reports, 2022. **41**(4).
- 454   23.   Nowowiejska, J., et al., *Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin—A*  
455           *New Potential Link in the Pathogenesis of Psoriasis.* International Journal of Molecular  
456           Sciences, 2023. **24**(17): p. 13047.

- 457 24. Lian, N., et al., *Gasdermin D-mediated keratinocyte pyroptosis as a key step in*  
458 *psoriasis pathogenesis*. Cell Death & Disease, 2023. **14**(9): p. 595.
- 459 25. Li, S., et al., *Gasdermin D in peripheral myeloid cells drives neuroinflammation in*  
460 *experimental autoimmune encephalomyelitis*. Journal of Experimental Medicine, 2019.  
461 **216**(11): p. 2562-2581.
- 462 26. Kim, S.H., et al., *Pellino-1 promotes intrinsic activation of skin-resident IL-17A-*  
463 *producing T cells in psoriasis*. Journal of Allergy and Clinical Immunology, 2023.  
464 **151**(5): p. 1317-1328.
- 465 27. Deng, G., et al., *Inhibition of NLRP3 inflammasome-mediated pyroptosis in*  
466 *macrophage by cycloastragenol contributes to amelioration of imiquimod-induced*  
467 *psoriasis-like skin inflammation in mice*. International Immunopharmacology, 2019. **74**:  
468 p. 105682.
- 469 28. Chiang, C.-C., et al., *Neutrophils in psoriasis*. Frontiers in immunology, 2019. **10**: p.  
470 2376.
- 471 29. Ding, Y., et al., *Mesenchymal stem/stromal cells primed by inflammatory cytokines*  
472 *alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis*. Cell Death &  
473 Disease, 2022. **13**(11): p. 996.
- 474 30. Xie, X., et al., *Single-cell transcriptome profiling reveals neutrophil heterogeneity in*  
475 *homeostasis and infection*. Nature immunology, 2020. **21**(9): p. 1119-1133.
- 476 31. Stackowicz, J., et al., *Neutrophil-specific gain-of-function mutations in Nlrp3 promote*  
477 *development of cryopyrin-associated periodic syndrome*. Journal of Experimental  
478 Medicine, 2021. **218**(10): p. e20201466.

- 479 32. Abram, C.L., et al., *Distinct roles for neutrophils and dendritic cells in inflammation and*  
480 *autoimmunity in motheaten mice*. *Immunity*, 2013. **38**(3): p. 489-501.
- 481 33. Zheng, X., et al., *The role and mechanism of pyroptosis and potential therapeutic*  
482 *targets in sepsis: a review*. *Frontiers in immunology*, 2021. **12**: p. 711939.
- 483 34. Aglietti, R.A. and E.C. Dueber, *Recent insights into the molecular mechanisms*  
484 *underlying pyroptosis and gasdermin family functions*. *Trends in immunology*, 2017.  
485 **38**(4): p. 261-271.
- 486 35. Shi, J., et al., *Cleavage of GSDMD by inflammatory caspases determines pyroptotic*  
487 *cell death*. *Nature*, 2015. **526**(7575): p. 660-665.
- 488 36. Wu, J., et al., *Treatment of severe acute pancreatitis and related lung injury by*  
489 *targeting gasdermin D-mediated pyroptosis*. *Frontiers in cell and developmental*  
490 *biology*, 2021. **9**: p. 780142.
- 491 37. Shi, H., et al., *GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R*  
492 *injury*. *Circulation research*, 2021. **129**(3): p. 383-396.
- 493 38. Al Mamun, A., et al., *Role of pyroptosis in spinal cord injury and its therapeutic*  
494 *implications*. *Journal of Advanced Research*, 2021. **28**: p. 97-109.
- 495 39. Verma, D., et al., *Enhanced inflammasome activity in patients with psoriasis promotes*  
496 *systemic inflammation*. *Journal of Investigative Dermatology*, 2021. **141**(3): p. 586-595.  
497 e5.
- 498 40. Zhang, C., et al., *Analysis of the potential pyroptosis mechanism in psoriasis and*  
499 *experimental validation of NLRP3 in vitro and in vivo*. *International*  
500 *Immunopharmacology*, 2023. **124**: p. 110811.

- 501 41. Wang, W.-M. and H.-Z. Jin, *Role of neutrophils in psoriasis*. Journal of Immunology  
502 Research, 2020. **2020**.
- 503 42. Cai, Y., et al., *A critical role of the IL-1 $\beta$ -IL-1R signaling pathway in skin inflammation*  
504 *and psoriasis pathogenesis*. Journal of investigative Dermatology, 2019. **139**(1): p.  
505 146-156.
- 506 43. Dąbrowska, D., et al., *Many ways—one destination: different types of neutrophils death*.  
507 International Reviews of Immunology, 2019. **38**(1): p. 18-32.
- 508 44. Mrowietz, U., et al., *Clinical use of dimethyl fumarate in moderate-to-severe plaque-*  
509 *type psoriasis: a European expert consensus*. Journal of the European Academy of  
510 Dermatology and Venereology, 2018. **32**: p. 3-14.
- 511 45. Mrowietz, U. and K. Asadullah, *Dimethylfumarate for psoriasis: more than a dietary*  
512 *curiosity*. Trends in molecular medicine, 2005. **11**(1): p. 43-48.
- 513 46. Humphries, F., et al., *Succination inactivates gasdermin D and blocks pyroptosis*.  
514 Science, 2020. **369**(6511): p. 1633-1637.  
515  
516

517 **Figure legends:**

518 Figure1. The GSDMD-mediated pyroptosis is activated in psoriasis.

519 a) Expression of GSDMD in patients with psoriasis patients and healthy people from GSE178197,  
520 GSE161683 and GSE153007.

521 b) Representative immunohistochemical staining of GSDMD in sections of skin tissue from  
522 healthy individuals and patients with psoriasis. Scale bar =100 $\mu$ m.

523 c) Schematic representation of the IMQ-induced psoriasis mouse model.

524 d) Representative images and statistical analysis of western blot analysis showing the expression  
525 of GSDMD and its N-terminal fragments in dorsal skin of WT mice treated with vehicle or  
526 IMQ at day 4.

527 e) Representative images and statistical analysis of western blot analysis showing the expression  
528 level of pro-caspase1 and caspase1 in dorsal skin of WT mice treated with vehicle or IMQ at day  
529 4.

530 psn, psoriasis non-lesional skin; ps, psoriasis skin; con, control; HD, healthy donor; PP, pustular  
531 psoriasis; IMQ, imiquimod; WT, wild-type. Error bars show mean  $\pm$  SEM. \*P < 0.05, \*\*P < 0.01,  
532 \*\*\*P < 0.001, \*\*\*\*P  $\leq$  0.0001. Data are representative of three independent experiments for (b, d,  
533 e).

534

535 Figure2. GSDMD deficiency mitigates psoriasis-like inflammation in mice.

536 a) Macroscopic phenotypic representation of the dorsal skin in WT and GSDMD-KO mice treated  
537 with IMQ at day 4.

538 b) Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=10-12).

539 c) Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal  
540 skin in WT and GSDMD-KO mice treated with IMQ at day 4 (n=5). Scale bar =100 $\mu$ m.

541 d) Representative images and statistical analysis of western blot analysis showing the expression  
542 level of GSDMD and caspase1 in dorsal skin of WT and GSDMD-KO mice treated with IMQ at  
543 day 4 (n=4).

544 e) Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in  
545 the dorsal skin of WT and GSDMD-KO mice treated with IMQ at day 4 (n = 4). Data were  
546 normalized to a reference gene, Gapdh.

547 f) ELISA analysis of IL-6 and IL-1 $\beta$  per 1 mg of the dorsal skin from WT and GSDMD-KO mice  
548 treated with IMQ at day 4 (n=5).

549 IMQ, imiquimod; WT, wild-type; KO, knockout; PASI, psoriasis Area and Severity Index. Error  
550 bars show mean  $\pm$  SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. Data are representative of three  
551 independent experiments for (a, c, d).

552

553

554 Figure3. Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.

555 a) Expression of GSDMD in neutrophils in psoriasis patients and healthy people from  
556 GSE123785.

557 b) Representative immunohistochemical staining of CD66b and GSDMD in two consecutive  
558 sections of skin tissue from patients with psoriasis vulgaris or generalized pustular psoriasis. Scale  
559 bar =100 $\mu$ m.

560 c) Dot plot of *Gsdmd* expression in each cell type in the skin of IMQ-induced psoriasis-like



561 mice (GSE165021).  
562 **d)** Representative immunofluorescence of GSDMD (red), Ly6G (green) and nuclear (blue) in  
563 dorsal skin of WT mice treated with vehicle, WT mice treated with IMQ and GSDMD-KO mice  
564 treated with IMQ at day 5. Scale bar =50 $\mu$ m.  
565 **e)** Representative and statistical graphs of the mean fluorescence intensity of propidium iodide in  
566 neutrophils from skin of WT mice as detected by flow cytometry(n=3).  
567 ps, psoriasis skin; con, control; PV, psoriasis vulgaris; GPP, generalized pustular psoriasis; IMQ,  
568 imiquimod; WT, wild-type; MFI, mean fluorescence intensity; PI, propidium iodide; MFO,  
569 Fluorescence Minus One. Error bars show mean  $\pm$  SEM. \*P < 0.05. Data are representative of  
570 three independent experiments for (b, d-e).

571

572

573 Figure4. GSDMD depletion in neutrophils attenuates the development of skin inflammation in  
574 psoriasis.

575 **a)** Representative images of western blot showing the expression of GSDMD in bone  
576 marrow-derived neutrophils of cKO and isotype control mice.

577 **b)** Macroscopic phenotypic representation of the dorsal skin in control and GSDMD-cKO mice  
578 treated with IMQ at day 4.

579 **c)** Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=7).

580 **d)** Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal  
581 skin in control and GSDMD-cKO mice treated with IMQ at day 4 (n=5). Scale bar =100 $\mu$ m.

582 **e)** Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in  
583 the dorsal skin of control and GSDMD-cKO mice treated with IMQ at day 4 (n = 4). Data were  
584 normalized to a reference gene, Gapdh.

585 **f)** ELISA analysis of IL-6 and IL-1 $\beta$  per 1 mg of the dorsal skin from control and GSDMD-cKO  
586 mice treated with IMQ at day 4(n=5).

587 **g)** Representative images and statistical analysis of western blot analysis showing the expression  
588 level of GSDMD and its N-terminal fragments in dorsal skin of WT, cKO and *Gsdmd*<sup>-/-</sup> mice  
589 treated with IMQ at day 4 (n=4).

590 **h)** Schematic representation of the use of anti-Ly6G antibody in the IMQ-induced psoriasis mouse  
591 model.

592 **i)** Macroscopic phenotypic representation and PASI score of cKO mice and control mice treated  
593 with IMQ and Ly6G antibody.

594

595 cKO, conditional knockout. Error bars show mean  $\pm$  SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

596 Data are representative of three independent experiments for (a, b, d, g, i).

597

598

599 Figure S1

600 **a)** Expression level of *Ly6g* in each cell type in the skin of IMQ-induced psoriasis-like mice  
601 (GSE165021).

602 **b)** Representative immunofluorescence of TUNEL (red), Ly6G (green) and nuclear (blue) in  
603 dorsal skin of WT mice treated with IMQ and GSDMD-KO mice treated with IMQ at day 4. Scale  
604 bar =50 $\mu$ m. Statistical analysis of ratio of TUNEL positive cells in neutrophils. (n=7)

605 c) Expression level of *S100a8* in each cell type in the skin of IMQ-induced psoriasis-like  
606 mice (GSE165021).

607 Error bars show mean  $\pm$  SEM. ns,  $P \geq 0.05$ . Data are representative of three independent  
608 experiments for (b).

609

610 Figure S2

611 a) Flow cytometry plots of neutrophil, isolated from dorsal skin of WT mice treated with IMQ.


612 b) Uniform Manifold Approximation and Projection (UMAP) of single cells isolated from the  
613 skin of IMQ-induced psoriasis-like mice (GSE165021), and feature plots showing  
614 expression of *Il17a*, *Il6*, *Tnfa*, *Il1b* and *Il18*.

615 Data are representative of three independent experiments for (a).


616

617


# Figure.1



## Figure.2



# Figure.3



# Figure 4

